Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05895500 · ClinicalTrials.gov registry record
Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
A clinical trial of Dry Eye and Asthenopia, sponsored by Nvision Laser Eye Centers.
- Completed
- Registry status
- 103
- Enrollment target
- 1
- Study location
NCT05895500: Completed study of Dry Eye and Asthenopia, sponsored by Nvision Laser Eye Centers.
NCT05895500 is a study of Dry Eye and Asthenopia that has completed, run by Nvision Laser Eye Centers. The registered enrollment target is 103 participants, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05895500, a study of Dry Eye and Asthenopia, has completed, sponsored by Nvision Laser Eye Centers.
- COMPLETED
- Registry status
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and Efficacy of Medications for Migraine in Patients with Dry Eye Disease or Asthenopia
Primary Outcome
Improvement in Symptoms: Number of days that a participant feels improvement in subjective symptoms of eye discomfort due to DED or asthenopia after oral administration of tablets over the 28-day Treatment Period (Days 1 to 28) compared to the 28-day Pretreatment Period (Day -28 to Day -1).
Conditions Studied
Interventions
- DRUG Injection for SC administration (120mg/syringe)
- DRUG Tablet (50mg/tablet), oral
Study Locations (1)
California
- NVision-EWEI-Torrance - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2023-11-09 |
What the finished NCT05895500 record still lists
NCT05895500 is an observational study that tracks outcomes without assigning an intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (11% higher).
The record links to 2 conditions, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Injection for SC administration (120mg/syringe) is the first listed.
NCT05895500 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05895500 about?
NCT05895500 is a clinical study titled "Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia". Safety and Efficacy of Medications for Migraine in Patients with Dry Eye Disease or Asthenopia
What is the current status of trial NCT05895500?
This trial is currently completed. The enrollment target is 103 participants. The study started on 2023-05-10. Estimated completion is 2023-11-09.
What conditions does trial NCT05895500 study?
This clinical trial studies the following conditions: Dry Eye, Asthenopia.
What interventions are being tested in trial NCT05895500?
The interventions under investigation include: Injection for SC administration (120mg/syringe) (DRUG), Tablet (50mg/tablet), oral (DRUG).
Who is sponsoring clinical trial NCT05895500?
This trial is sponsored by Nvision Laser Eye Centers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05895500 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05895500's enrollment target sits among peer trials
103 12th of 41 higher than 30 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
The THINK Study Incidence of Neurotrophic Keratopathy)
RECRUITING · NA
-
Low Level Light Therapy & Skin Pigmentation
RECRUITING · NA
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI